FDA Cleared New Solid Tumor Trial Platform
The STARFISH-54 trial platform will test PharmaMar's PM54 therapy in combination with existing cancer drugs.
Updated on Sept. 23, 2026 in Cancer
Live Poll
Do you support prioritizing faster clinical trial processes over traditional, slower evaluation methods?
The U.S. Food and Drug Administration has granted clearance for the STARFISH-54 platform trial to study the therapeutic agent PM54. This new framework aims to evaluate combinations of the drug with other therapies for patients with solid tumors.
Why it matters
The trial utilizes a platform design to evaluate multiple treatment combinations simultaneously, which may accelerate the clinical development process. This approach allows researchers to study new options for solid tumors more efficiently than traditional, single-study protocols.
The STARFISH-54 platform trial has received regulatory approval to begin testing combinations of the investigational agent PM54. The initial sub-studies are authorized to examine PM54 alongside irinotecan and doxorubicin, respectively.
The players
U.S. Food and Drug Administration
The federal agency responsible for regulating pharmaceuticals, medical devices, and public health safety in the United States.
PharmaMar
A pharmaceutical company specializing in the discovery and development of innovative oncology treatments for various cancers.
The details
The STARFISH-54 trial uses a platform protocol, which allows for the simultaneous evaluation of multiple combination therapies under a single master study structure. This design enables investigators to add or remove treatment cohorts as new scientific evidence emerges throughout the development process. By using one common protocol for different combinations, the trial aims to streamline the assessment of PM54 in patients with various solid tumor types.
Timeline
September 23, 2026: PharmaMar announced that the FDA cleared the STARFISH-54 trial.
Health Landscape
The STARFISH-54 trial follows the precedent of adaptive platform trials in oncology, which have transformed the traditional paradigm of testing single treatments individually. This approach reflects a broader trend toward more efficient, modular research designs in cancer therapy development.
Platform trials like this are designed to speed up the research process, potentially bringing new treatment options to patients with solid tumors faster than traditional methods. If you are currently managing a solid tumor diagnosis, discuss with your physician whether clinical trials might be appropriate for your care plan.
The takeaway
The STARFISH-54 platform trial represents a shift toward more efficient, multi-arm clinical research for solid tumors. Patients and caregivers should remain in close communication with their oncology care team to stay informed about available clinical trial options that align with their diagnosis.
Further reading
For more information on how new treatment protocols are developed, visit the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you support prioritizing faster clinical trial processes over traditional, slower evaluation methods?
